Two optical treatment modalities have accumulated the strongest evidence base for slowing pediatric myopia progression ...
João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means ...
John W. Kitchens, MD, discusses patient selection for geographic atrophy treatment, counseling approaches, and emerging ...
Zhang traced growing interest in home tonometry back to the COVID-19 pandemic, when clinicians needed new ways to track patie ...
Japan's Ministry of Health, Labour and Welfare (MHLW) granted orphan drug designation to gildeuretinol acetate (ALK-001; Alkeus Pharmaceuticals) for Stargardt disease, a status that unlocks ...
A peer-reviewed study evaluating serial application of decellularized basement membrane (DBM) (Biovance Ocular; DefEYE) in patients with subclinical or Mackie Stage 1 neurotrophic keratitis (NK) found ...
Angela Y. Zhu, MD, of Bascom Palmer Eye Institute, explains how to distinguish eye allergy from vision-threatening VKC and ...
Vitreoretinal specialist Dante Pieramici, MD, of California Retina Consultants breaks down the phase 3 COMO and CAPRI trials ...
Dante Pieramici, MD, of California Retina Consultants, framed the sustained-delivery tyrosine kinase inhibitor (TKI) EYP-1901 ...
Jonathan Gloth, MD, explains how MK-8748's dual Tie2 agonist/VEGF inhibitor mechanism differs from VEGF blockade alone, and ...
In this episode of The Retina TL;DR with Dr. Weng, powered by Modern Retina, host Christina Y. Weng, MD, MBA, FASRS, ...
A former US Navy flight surgeon turned three-time CMO, David J. Tanzer, MD, ABO, reflects on a career built at the pharma-clinic bridge.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results